Skip to main content

Table 1 Performance characteristics of careHPV assay for the detection of 14 high-risk (hr) HPV genotypes compared with HPV genotyping among 175 women in Cape Coast, Ghana

From: Options in human papillomavirus (HPV) detection for cervical cancer screening: comparison between full genotyping and a rapid qualitative HPV-DNA assay in Ghana

  All women (N = 175)
% (95% CI)
HIV-1 seropositive women (N = 94)
% (95% CI)
HIV seronegative women (N = 81)
% (95% CI)
* P-value
hr-HPV prevalence 55.0 (48.0–62.9) 79.0 (69.0–86.5) 28.0 (19.0–39.5) 0.0001
Sensitivity 96.9 (91.2–99.4) 97.3 (90.6–99.7) 95.7 (78.1–99.9) 0.50
Specificity 91.0 (82.4–96.3) 85.0 (62.1–96.8) 93.1 (83.3–98.1) 0.10
PPV 93.1 (86.2–97.2) 96.0 (88.8–99.2) 84.6 (65.1–95.6) 0.01
NPV 95.9 (88.8–99.2) 89.5 (66.9–98.7) 98.2 (90.3–100.0) 0.02
Agreement 94.3 (89.7–97.2) 94.7 (88.0–98.3) 93.8 (86.2–98.0) 0.77
Kappa value (95%CI) 0.88 (0.81–0.95) 0.84 (0.70–0.98) 0.85 (0.73–0.98) 0.86
P-value for Kappa <0.0001 <0.0001 <0.0001  
  1. PPV positive predictive valuem, NPV negative predictive value
  2. * comparing HIV-1 seropositive and HIV-seronegative women